Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.45
CLVS's Cash-to-Debt is ranked lower than
76% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. CLVS: 1.45 )
Ranked among companies with meaningful Cash-to-Debt only.
CLVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.91  Med: N/A Max: No Debt
Current: 1.45
Equity-to-Asset 0.33
CLVS's Equity-to-Asset is ranked lower than
84% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CLVS: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
CLVS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.54 Max: 0.75
Current: 0.33
0.33
0.75
Piotroski F-Score: 4
Altman Z-Score: 2.67
Beneish M-Score: -3.53
WACC vs ROIC
12.66%
-992.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -4882.09
CLVS's Operating Margin % is ranked lower than
90% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. CLVS: -4882.09 )
Ranked among companies with meaningful Operating Margin % only.
CLVS' s Operating Margin % Range Over the Past 10 Years
Min: -477862.82  Med: -239512.91 Max: -1163
Current: -4882.09
-477862.82
-1163
Net Margin % -4601.86
CLVS's Net Margin % is ranked lower than
90% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. CLVS: -4601.86 )
Ranked among companies with meaningful Net Margin % only.
CLVS' s Net Margin % Range Over the Past 10 Years
Min: -447611.54  Med: -224393.04 Max: -1174.54
Current: -4601.86
-447611.54
-1174.54
ROE % -282.84
CLVS's ROE % is ranked lower than
93% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. CLVS: -282.84 )
Ranked among companies with meaningful ROE % only.
CLVS' s ROE % Range Over the Past 10 Years
Min: -282.84  Med: -83.7 Max: -26.78
Current: -282.84
-282.84
-26.78
ROA % -67.20
CLVS's ROA % is ranked lower than
75% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. CLVS: -67.20 )
Ranked among companies with meaningful ROA % only.
CLVS' s ROA % Range Over the Past 10 Years
Min: -144.39  Med: -51.12 Max: -21.25
Current: -67.2
-144.39
-21.25
ROC (Joel Greenblatt) % -7315.48
CLVS's ROC (Joel Greenblatt) % is ranked lower than
84% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. CLVS: -7315.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CLVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9748.56  Med: -7941.19 Max: -3834.63
Current: -7315.48
-9748.56
-3834.63
3-Year EBITDA Growth Rate 48.70
CLVS's 3-Year EBITDA Growth Rate is ranked higher than
88% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. CLVS: 48.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CLVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53.4  Med: 8.65 Max: 51.8
Current: 48.7
-53.4
51.8
3-Year EPS without NRI Growth Rate 45.40
CLVS's 3-Year EPS without NRI Growth Rate is ranked higher than
89% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. CLVS: 45.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CLVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -53.1  Med: 7.15 Max: 48.8
Current: 45.4
-53.1
48.8
GuruFocus has detected 4 Warning Signs with Clovis Oncology Inc $CLVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CLVS's 30-Y Financials

Financials (Next Earnings Date: 2017-08-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:NBIX, NAS:TECH, NAS:GLPG, NAS:BLUE, NAS:ARIA, OTCPK:PPTDF, NAS:ACAD, OTCPK:BTGGF, NAS:ICPT, NAS:PBYI, NAS:PTLA, NAS:SAGE, NAS:NKTR, NAS:JUNO, NYSE:XON, NAS:CBPO, NAS:AGIO, NAS:KITE, NAS:RARE, NAS:LGND » details
Traded in other countries:C6O.Germany,
Headquarter Location:USA
Clovis Oncology Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its commercial product is Rubraca.

Clovis Oncology Inc is operative in the healthcare sector based in the United States. As a pharmaceutical manufacturer, it is focused on developing and commercializing anti-cancer agents. Its suite of product candidates includes Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor for the treatment of non-small cell lung cancer. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. The company's revenue primarily depends on the sale of Rucaparib in the United States market.

Ratios

vs
industry
vs
history
PB Ratio 24.07
NAS:CLVS's PB Ratio is ranked lower than
95% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. NAS:CLVS: 24.07 )
Ranked among companies with meaningful PB Ratio only.
NAS:CLVS' s PB Ratio Range Over the Past 10 Years
Min: 1.28  Med: 4.27 Max: 24.87
Current: 24.07
1.28
24.87
PS Ratio 584.79
NAS:CLVS's PS Ratio is ranked lower than
95% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. NAS:CLVS: 584.79 )
Ranked among companies with meaningful PS Ratio only.
NAS:CLVS' s PS Ratio Range Over the Past 10 Years
Min: 31.02  Med: 132.36 Max: 604.88
Current: 584.79
31.02
604.88
Current Ratio 7.28
NAS:CLVS's Current Ratio is ranked higher than
70% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NAS:CLVS: 7.28 )
Ranked among companies with meaningful Current Ratio only.
NAS:CLVS' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 9.19 Max: 31.09
Current: 7.28
0.86
31.09
Quick Ratio 7.17
NAS:CLVS's Quick Ratio is ranked higher than
71% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:CLVS: 7.17 )
Ranked among companies with meaningful Quick Ratio only.
NAS:CLVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 9.19 Max: 31.09
Current: 7.17
0.86
31.09
Days Inventory 309.31
NAS:CLVS's Days Inventory is ranked lower than
86% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 131.03 vs. NAS:CLVS: 309.31 )
Ranked among companies with meaningful Days Inventory only.
NAS:CLVS' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 309.31
Current: 309.31
0
309.31
Days Sales Outstanding 123.20
NAS:CLVS's Days Sales Outstanding is ranked lower than
79% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. NAS:CLVS: 123.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
NAS:CLVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.86  Med: 313.54 Max: 566.22
Current: 123.2
60.86
566.22
Days Payable 5.00
NAS:CLVS's Days Payable is ranked lower than
89% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 54.41 vs. NAS:CLVS: 5.00 )
Ranked among companies with meaningful Days Payable only.
NAS:CLVS' s Days Payable Range Over the Past 10 Years
Min: 5  Med: 56898.29 Max: 56898.29
Current: 5
5
56898.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.50
NAS:CLVS's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. NAS:CLVS: -4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NAS:CLVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -194.7  Med: -14.2 Max: -4.5
Current: -4.5
-194.7
-4.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 89.96
NAS:CLVS's Price-to-Net-Cash is ranked lower than
96% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 7.66 vs. NAS:CLVS: 89.96 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NAS:CLVS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.45  Med: 11.75 Max: 91.34
Current: 89.96
2.45
91.34
Price-to-Net-Current-Asset-Value 63.22
NAS:CLVS's Price-to-Net-Current-Asset-Value is ranked lower than
96% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. NAS:CLVS: 63.22 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NAS:CLVS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.43  Med: 11.04 Max: 64.19
Current: 63.22
2.43
64.19
Price-to-Tangible-Book 43.92
NAS:CLVS's Price-to-Tangible-Book is ranked lower than
97% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. NAS:CLVS: 43.92 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NAS:CLVS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.39  Med: 10.11 Max: 396.95
Current: 43.92
2.39
396.95
Price-to-Median-PS-Value 4.42
NAS:CLVS's Price-to-Median-PS-Value is ranked lower than
93% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. NAS:CLVS: 4.42 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NAS:CLVS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.78  Med: 1.05 Max: 4.49
Current: 4.42
0.78
4.49
Earnings Yield (Greenblatt) % -8.45
NAS:CLVS's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. NAS:CLVS: -8.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NAS:CLVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -70.4  Med: -10.1 Max: -3.9
Current: -8.45
-70.4
-3.9

More Statistics

Revenue (TTM) (Mil) $7.05
EPS (TTM) $ -8.23
Beta1.86
Short Percentage of Float20.92%
52-Week Range $11.57 - 96.92
Shares Outstanding (Mil)48.69

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 53 217 470
EPS ($) -4.37 -2.18 2.07
EPS without NRI ($) -4.37 -2.18 2.07
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}